Good morning ... Whatever you did this weekend instead of watching the royal wedding, I hope you enjoyed it.

1 big thing: GOP is quiet on Trump’s drug plan

Giphy

The public wants cheaper prescription drugs. President Trump has a plan to lower the cost of prescription drugs. Republicans, ahead of this year’s midterms, want to please voters, and many of them want to yoke themselves to Trump.

Yet they’re not saying much about Trump’s plan.

Some strategists think that’s a mistake. “Standing with Big Pharma against Trump seems like political suicide if you're a Republican in Congress," Alex Conant, a former Sen. Marco Rubio aide who now runs a strategy firm, told Axios’ Caitlin Owens. (Conant’s firm has clients that support policies pharma opposes).

Threat level: Republican lawmakers are caught between two competing interests — most of them want to be on Trump’s side, but also on the pharmaceutical industry’s side.

The thing is, though, Trump’s plan is not particularly hard on the industry. Yes, industry opposes some important parts of it, but there’s a reason drugmakers’ stocks went up on the day it was announced.

To be sure: There’s still plenty of time. "The proposal was just released, and I think members are getting their heads around it," said Rep. Tom Cole, who is close to House leadership

2. Theranos: It wasn’t just Elizabeth Holmes

Photo: JP Yim/Getty Images

“Bad Blood” — the book from John Carreyrou, the Wall Street Journal reporter who exposed Theranos’ many deceptions — is out today. And to whet our appetites, Carreyrou has an excerpt today in the WSJ focused on Ramesh “Sunny” Balwani.

Balwani hasn’t gotten as much attention as founder Elizabeth Holmes, but as her partner and enforcer, he was just as big a part of Theranos’ story, Carreyrou writes.

“He frequently barked orders and dressed people down, former employees say. They remember him cutting a brash figure among the scientists and engineers, wearing white designer shirts with puffy sleeves and the top three buttons open, acid-washed jeans and blue Gucci loafers, along with pungent cologne.”

“During one meeting, he latched onto the term ‘end effector,’ which signifies the claw at the end of a robotic arm. Except Mr. Balwani didn’t hear ‘end effector’ — he heard ‘endofactor.’ For the rest of the meeting, he kept referring to the fictional endofactors."

"Negative Glassdoor reviews about the company weren’t unusual; Mr. Balwani made sure they were balanced out by a steady flow of fake positive reviews he ordered members of the HR department to write, according to former employees."